5' CpG Island méthylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

Nature Medicine

Volumn 1, Issue 7, 1995, Pages 686-692

  Merlo, Adrian ^a   Herman, James G ^b   Mao, Li ^a   Lee, Daniel J ^a   Gabrielson, Edward ^c   Burger, Peter C ^c   Baylin, Stephen B ^b   Sidransky, David ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLIN DEPENDENT KINASE; DNA; RNA;

ALLELE; ARTICLE; CHROMOSOME 9P; CONTROLLED STUDY; GENE ACTIVATION; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; METHYLATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

ALLELES; AZACITIDINE; BASE SEQUENCE; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 9; COMPARATIVE STUDY; CPG ISLANDS; CYTOSINE; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOMA; HEAD AND NECK NEOPLASMS; HUMAN; LUNG NEOPLASMS; METHYLATION; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN P16; SEQUENCE DELETION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0029011539     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0795-686     Document Type: Article

References (47)

1. Fearon, E.R. and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
2. Weinberg, R.A. Tumor suppressor genes. Science 254, 1138-1146 (1991).
3. Nowell, P.C. Clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
4. Sidransky, D. et al. Clonal origin of bladder cancer. New Engl. J. Med. 326, 737-740 (1992).
5. Sidransky, D. et al. Clonal expansion of pS3 mutant cells is associated with brain tumour progression. Nature 355, 846-847 (1992).
6. Sidransky, D. et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256, 102-105 (1992).
7. Sidransky, D. et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706-709 (1991).
8. Mao, L., Hruban, R.H., Boyle, J.O., Tockman, M. and Sidransky, D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 54, 1634-1637 (1994).
9. Mao, L. et al. Microsatellite alterations as clonal markers in the detection of human cancer. Proc. natn. Acad. Sci. USA. 91, 9871-9875 (1994).
10. Cairns, P., Shaw, M.E. and Knowles, M.A. Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene 8, 1083-1085 (1993).
11. van der Riet, P. et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res. 54, 1156-1158 (1994).
12. Olopade, O.I. et al. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 14, 437-443 (1992).
13. Merlo, A., Gabrielson, E., Askin, F. and Sidransky, D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res. 54, 640-642 (1994).
14. Merlo, A. etal. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res. 54, 2322-2326 (1994).
15. Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440 (1994).
16. Noborl, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756 (1994).
17. Serrano, M., Hannon, G.J. and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707 (1993).
18. Sherr, CJ. Mammalian G1 cydins. Cell 73, 1059-1065 (1993).
19. Hussussian, C.J. et al. Germline pl6 mutations in familial melanoma. Nature Genet. 8, 15-21 (1994).
20. Kamb, A. et al. Analysis of the pl6 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 22-26 (1994).
21. Caldas, C. et al. Frequent somatic mutations and homozygous deletions of the pl6 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 8, 27-32 (1994).
22. Mori, T. et al. Frequent somatic mutation of MTS1/CDK4I (multiple tumor sup- pressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54, 3396-3397 (1994).
23. Serrano, M., Gomez-Lahoz, E., DePinho, R.A., Beàch, D, and Bar-Sagi, D. Inhibition of ras-induced proliferation and cellular transformation by pl6INK4. Science 267, 249-252 (1995).
24. Arap, W., Nishikawa, R., Fumari, F.B., Cavenee, W.K. and Huang, H-J. Replacement of the pl6/CDKN2 gene suppresses glioma cell growth. Cancer Res. 55, 1351-1354 (1995).
25. Caims, P, etal. Rates of pl6 (MTS1) mutations in primary tumors with 9p loss. Science 265, 415-416 (1994).
26. Spruck, C.H. et al. pl6 gene in uncultured tumours. Nature 370, 183-184 (1994).
27. Zhang, S.-Y. et al. Higher frequency of alterations in the pl6/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res. 54, 5050-5053 (1994).
28. Xu, L. et al. Mutational analysis of CDKN2 (MTSl/pl6INK4) in human breast carcinomas. Cancer Res. 54, 5262-5264 (1994).
29. Okamoto, A. et al. Mutations and altered expression of genes regulating the cell cycle G1 checkpoint in human cancer. Proc. natn. Acad. Sci. U.S.A. 91, 11045-11049 (1994).
30. Issa, J-P. J. et al. Méthylation of the oestrogen receptor CpG island links aging and neoplasia in human colon. Nature Genet. 7, 536-540 (1994).
31. Herman, J.G. et al. Silencing of the VHL tumor suppressor gene by DNA méthylation in renal carcinoma, Proc. natn. Acad. Sci. U.SA. 91, 9700-9704 (1994).
32. Bird, A.P. CpG-rich islands and the function of DNA méthylation. Nature 321, 209-213 (1986).
33. Bird, A. The essentials of DNA méthylation. Cell 70, 5-8 (1992).
34. Migeon, B.R. Insights into X chromosome inactivation from studies of species variation, DNA méthylation and replication, and vice versa. Genet. Res. 56, 91-98 (1990).
35. Li, E., Beard, C. St Jaenisch, R. Role for DNA méthylation in genomic imprinting. Nature 366, 362-365 (1993).
36. Sakai, T. et al. Allele-specific hyperméthylation of the retinoblastoma tumorsuppressor gene. Am. J. hum. Genet. 48, 880-888 (1991).
37. Latif, F. et al. Chromosome 3p deletions in head and neck carcinomas: Statistical ascertainment of allelic loss. Cancer Res. 52, 1451-1456 (1992).
38. Mao, L. et al. A novel p16™ transcript. Cancer Res. (in the press).
39. Antequera, F., Boyes, J. St Bird, A. High levels of de novo méthylation and altered chromatin structure at CpG islands in cell lines. Cell 62, 503-514 (1990).
40. Knudson, A.G. Mutation and cancer: Statistical study of retinoblastoma. Proc. natn. Acad. Sci. USA. 68, 820-823 (1971).
41. de Bustros, A. et al. The short arm of chromosome 11 is a "hot spot" for hyperméthylation in human neoplasia. Proc. natn. Acad. Sci. USA. 85, 5693-5697 (1988).
42. Baylin, S.B. et al. Abnormal pattern of DNA méthylation in human neoplasia: Potential consequences for tumor progression. Cancer Cells 3, 383-390 (1991).
43. Rygaard, K., Sorensen, G.D., Pettengill, O.S., Cate, C.C. St Spang-Thomsen, M. Abnormalities in structure and expression of the retinoblastoma gene in small cell lung cancer cell lines and xenografts in nude mice. Cancer Res. 50, 5312-5317 (1990).
44. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. New Engl. J. Med. 319, 525-532 (1988).
45. Feinberg, A.P. St Vogelstein, B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Annal. Biochem. 137, 266-267 (1984).
46. van der Riet, P. et al. Progression of basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele. Cancer Res. 54, 25-27 (1994).
47. Chomczynski, P. Sr Sacchi, N. Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Analyt. Biochem. 162, 156-159 (1987).